High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Abstract Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cell renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient outcomes. These unsuccessful ICI trials suggest that the tumour infiltrating immunophenotypes, termed here as the immune cell types, states and their spatial location within the tumour microenvironment (TME), were unfavourable for ICI treatment. Defining the tumour infiltrating immune cells may assist with the identification of predictive immunophenotypes within the TME that are favourable for ICI treatment. To define the immunophenotypes within the ccRCC TME, fresh para-tumour (pTME, n = 2), low-grade (LG, n = 4, G1-G2) and high-grade (HG, n = 4, G3-G4) tissue samples from six patients with ccRCC presenting at a tertiary referral hospital underwent spatial transcriptomics sequencing (ST-seq). Within the generated ST-seq datasets, immune cell types and states, termed here as exhausted/pro-tumour state or non-exhausted/anti-tumour state, were identified using multiple publicly available single-cell RNA and T-cell receptor sequencing datasets as references. HG TMEs revealed abundant exhausted/pro-tumour immune cells with no consistent increase in expression of PD-1, PD-L1 and CTLA4 checkpoints and angiogenic genes. Additional HG TME immunophenotype characteristics included: pro-tumour tissue-resident monocytes with consistently increased expression of HAVCR2 and LAG3 checkpoints; an exhausted CD8 + T cells sub-population with stem-like progenitor gene expression; and pro-tumour tumour-associated macrophages and monocytes within the recurrent TME with the expression of TREM2 . Whilst limited by a modest sample size, this study represents the largest ST-seq dataset on human ccRCC. Our study reveals that high-risk ccRCC TMEs are infiltrated by exhausted/pro-tumour immunophenotypes lacking specific checkpoint gene expression confirming that HG ccRCC TME are immunogenic but not ICI favourable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, outcomes from adjuvant ICI trials for localized ccRCC have not shown improvements in survival (Raghubar et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Raghubar et al., 2023
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“These con fl icting trial outcomes of ICIs within intermediate high-risk ccRCC do not diminish the reported improved survival outcomes within the metastatic setting 42 – 44 .”
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 1×
“Approved fi rst-line systemic therapy for metastatic ccRCC includes immunotherapies such as immune checkpoint inhibitors (ICIs) that serve to reactivate anti-tumour immune responses 1,3 – 10 .”
Hafemeister, C., & Satija, R. (2019) · Genome Biology · doi:10.1186/s13059-019-1874-1 · Cited by 4,479 · cited 2×
“Then, we merged all the individual ST-seq datasets and removed batch effects due to individual patient samples using the SCTransformfunction in Seurat 58 .”
InfluentialPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · cited 1×
“Approved fi rst-line systemic therapy for metastatic ccRCC includes immunotherapies such as immune checkpoint inhibitors (ICIs) that serve to reactivate anti-tumour immune responses 1,3 – 10 .”
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087 · cited 1×
“It will be of interest to investigate within ex vivo studies, if these exhausted stem-like progenitors CD8 + T cells can be switched to an anti-tumour mode with ICI, as reported in other cancers 34 – 39 .”
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053 · cited 1×
“It will be of interest to investigate within ex vivo studies, if these exhausted stem-like progenitors CD8 + T cells can be switched to an anti-tumour mode with ICI, as reported in other cancers 34 – 39 .”
Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679
Cited by
Zhu, Z., Jin, Y., Zhou, J., Chen, F., Chen, M., Gao, Z., Hu, L., Xuan, J., Li, X., Song, Z., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02059-y · Cited by 99
“The types and status of immune cells infiltrating tumors may help predict responses to ICI therapy [133].”
BackgroundSpatial transcriptomics in cancer research and potential clinical impact: a narrative review
Cilento, M. A., Sweeney, C. J., & Butler, L. M. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05816-0 · Cited by 99
“…into the immunogenic TME of tumors that have abundant exhausted/pro-tumor immune cells and provided clues to mechanisms explaining the infrequent lack of response to immunotherapy, including exhausted immune cells and lack of expression of the PD-1 , PD-L1 and CTLA4 genes (Raghubar et al. 2023).”
BackgroundTREM2+ macrophages: a key role in disease development
Wang, X., Wang, Y., Yang, L. X., Zhang, Y., & Yang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550893 · Cited by 43
Current understanding on TREM-2 molecular biology and physiopathological functions
Bharadwaj, S., Groza, Y., Mierzwicka, J. M., & Malý, P. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112042 · Cited by 25
Choi, S.-W., Kim, J. H., Hong, J., & Kwon, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568590 · Cited by 24
Metadata
- Authors
- Raghubar, A. M., Matigian, N. A., Crawford, J., Francis, L., Ellis, R., Healy, H. G., Kassianos, A. J., Ng, M. S. Y., Roberts, M. J., Wood, S., & Mallett, A. J.
- Affiliations
- Queensland Health (AU)
- The University of Queensland (AU)
- Corresponding author
- Mallett, Andrew J.
- ORCID
- Venue
- npj Precision Oncology
- Published
- 2023-09-11
- Volume
- 7
- Issue
- 1
- Pages
- 88-88
- ISSN
- 2397-768X (ISSN-L)
- PMC
- PMC10495390
- OpenAlex
- W4386603347
- Cited by
- 26
- References
- 61
- Citations by year
- 2026: 12 · 2025: 7 · 2024: 6 · 2023: 1
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Precision Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ResearchOnline - JCU (James Cook University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Queensland Health Advancing Clinical Research Fellowship
- Australian Government Research Training Program Scholarship
- Royal Brisbane and Women’s Hospital Foundation 2020 Robert and Janelle Bird Postdoctoral Research Fellowship
- Metro North Hospital and Health Service Clinical Research Fellowship
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- clear cell renal cell carcinoma, tumor microenvironment, immune checkpoint inhibitors, immune exhaustion, spatial transcriptomics, tumour-associated macrophages, CD8+ T cells, PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, TREM2, tumor grade, immunogenicity, predictive biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints. https://app.cochat.ai/papers/10.1038/s41698-023-00441-5
- The paper
- Raghubar, A. M., Matigian, N. A., Crawford, J., Francis, L., Ellis, R., Healy, H. G., Kassianos, A. J., Ng, M. S. Y., Roberts, M. J., Wood, S., & Mallett, A. J. (2023). High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints. npj Precision Oncology. https://doi.org/10.1038/s41698-023-00441-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.